CardioExchange Archive

March 10th, 2013

ACC.13: Is Cangrelor an Antiplatelet CHAMPION?

Deepak L. Bhatt, MD, MPH, Richard A. Lange, MD, MBA and L. David Hillis, MD

Deepak Bhatt sheds light on findings from the CHAMPION PHOENIX trial and their implications for clinical practice.

---

February 12th, 2013

ACC and STS Break New Ground to Test TAVR for Unapproved Uses

Larry Husten, PHD

In a startling break with tradition, the American College of Cardiology (ACC) and the Society of Thoracic Surgeons (STS) will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR). The two medical groups have recently been granted an investigational device exemption (IDE) by the FDA for one such […]

---

January 22nd, 2013

Trials of Niacin and AF Device Will Headline American College of Cardiology Program

Larry Husten, PHD

Two big trials will highlight this year’s American College of Cardiology (ACC) meeting in March in San Francisco. First is the PREVAIL trial testing Boston Scientific’s long-anticipated Watchman left atrial appendage closure device for stroke prevention in patients with atrial fibrillation (AF). Second is the detailed presentation of the controversial failed HPS2-THRIVE trial of extended-release niacin and laropiprant. The […]

---

October 3rd, 2012

ACC Fellows in Training Push Congress for Sustainable Health Care Reform

Michael Tempelhof, MD MSc

Dr. Michael Tempelhof, one of the ACC’s Fellows in Training, discusses the group’s efforts to lobby Congress for a restructured health care program, emphasizing high-quality, evidence-based medicine.

---

December 30th, 2011

CYP2C19 Genotyping: Down For The Count?

Richard A. Lange, MD, MBA and L. David Hillis, MD

The controversy over the use of genetic testing to guide antiplatelet therapy reminds us of a WWF (Worldwide Wrestling Federation) tag team match.   What we agree upon (the match rules): Clopidogrel is a prodrug activated by several enzymes, including CYP2C19, and common genetic variations alter CYP2C19 activity. Here’s where the wrestling match begins: Are the CYP2C19 genetic […]

---

June 27th, 2011

TAVI: Playing in the Sandbox Together

Richard A. Lange, MD, MBA and L. David Hillis, MD

Kudos to the the American College of Cardiology Foundation (ACCF) and the Society of Thoracic Surgeons (STS) for getting ahead of the game by rolling out a joint position statement regarding transcatheter aortic valve implantation (TAVI) before the FDA panel convenes in July to consider approval of the procedure.  It’s a terrific first step to avoid some of the […]

---

April 1st, 2011

Who’s Paying for the Fellows?

John Ryan, MD

Several Cardiology Fellows who are attending ACC.11 this week are blogging together on CardioExchange. The Fellows include Sandeep Mangalmurti, Hansie Mathelier, John Ryan (moderating and providing an outsider’s view from Chicago), Amit Shah, and Justin Vader. See the next post in this series, and check back often to learn about the biggest buzz in New Orleans. […]

---

March 31st, 2011

A Delectable Side Benefit of ACC — New Orleans Restaurants

John Ryan, MD

Obviously, the emphasis at ACC is on science and research. However, we all know that these meetings provide unique opportunities for reunions and social events for traveling cardiologists. For me, one of the highlights of any meeting is when my faculty arranges a dinner or when I can get away with others from the stressors […]

---

March 25th, 2011

A Meeting That Could Change How You Practice

John Ryan, MD

There is a lot on offer this year at ACC in New Orleans. Whether you are going to live the high life and dine at the Commanders Palace, or crank out the karaoke tunes at Cat’s Meow on Bourbon Street, most fellows lucky enough to attend ACC this year will come away with a vision […]

---

September 24th, 2010

ACC Will Co-Sponsor TCT Symposium in 2011

Larry Husten, PHD

The American College of Cardiology (ACC) will be a co-sponsor of the TCT Symposium in 2011, the ACC and the Cardiovascular Research Foundation (CRF) announced on Thursday. The arrangement will deepen the existing relationship between the two organizations, which already collaborate on the Innovations in Interventions (i2) Summit at ACC’s Annual Scientific Sessions. In a blog post, […]

---